[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue.
  • BACKGROUND: We previously reported that caffeine-potentiated chemotherapy induced significantly good response in patients with musculoskeletal sarcomas.
  • In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • PATIENTS AND METHODS: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • Good responses (gross tumor shrinkage >30%, or histologically >90% necrosis) to chemotherapy were seen in all five patients.
  • Survival time was >1 year in all patients, and three out of five patients presented no evidence of local recurrence or metastasis at the final follow-up.
  • CONCLUSION: Caffeine-potentiated chemotherapy may be of benefit for malignant tumors other than musculoskeletal sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Caffeine / pharmacology. Carcinoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


2. Ruiz-Hernández G, Delgado-Bolton RC, Rubio-Pérez MJ, Jiménez-Vicioso A, Pérez-Castejón MJ, Carreras-Delgado JL: [Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET]. Rev Esp Med Nucl; 2005 Sep-Oct;24(5):326-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET].
  • [Transliterated title] Recurrencia de un carcinoma gástrico de células en anillo de sello demostrada por PET-FDG.
  • OBJECTIVE: To present the case report of a patient with undifferentiated and diffuse signet-ring cell gastric carcinoma in which FDG-PET evidenced recurrent disease.
  • MATERIALS AND METHODS: The patient was diagnosed of a stage III gastric carcinoma in 1994 and was treated with a subtotal gastrectomy.
  • The patient was treated with chemotherapy and radiotherapy, reaching a complete response.
  • CONCLUSIONS: In this case report we stress the importance of early recurrence by FDG-PET in a non-intestinal gastric carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194466.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Pandey M, Kumar V, Shukla M, Kumar M: Thyroid swelling in a 32-year-old male. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The further diagnostic and metastatic work-up identified a diffuse carcinoma of the stomach as the primary site with liver as secondary and retroperitoneal lymph nodes having mucinous deposits with associated Peutz-Jeghers polyposis.
  • This is the first report in the English literature of intrathyroidal metastasis from carcinoma of the stomach with Peutz-Jeghers polyposis presenting primarily as a thyroid swelling.
  • Preoperative diagnosis, proper evaluation and high degree of suspicion may avoid unnecessary thyroidectomy and effective palliation can be achieved with chemotherapy in view of disseminated disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):581-7 [16983577.001]
  • [Cites] Anticancer Res. 2008 Sep-Oct;28(5B):2885-8 [19031929.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):896-9 [9634427.001]
  • [Cites] World J Surg. 1999 Feb;23(2):177-80; discussion 181 [9880428.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):127-35 [9916927.001]
  • (PMID = 21686341.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028274
  •  go-up   go-down


Advertisement
4. Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Ohira M, Miwa A, Hirakawa K: Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer; 2009 Oct 6;101(7):1100-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model.
  • METHODS: Ki23057 was administered orally to gastric cancer models created by orthotopic inoculation of diffuse-type gastric cancer cells, OCUM-2MLN.
  • Murine gastric cancer models created by the orthotopic inoculation of OCUM-2MLN cells showed the diffusely infiltrating growth and frequently developed LN metastasis.
  • CONCLUSION: The inhibition of lymphangiogenesis targeting VEGFR-3 phosphorylation is a therapeutic strategy for inhibiting LN metastasis of diffuse-type gastric cancer.
  • [MeSH-major] Lymphatic Metastasis / prevention & control. Quinolines / therapeutic use. Stomach Neoplasms / drug therapy. Vascular Endothelial Growth Factor Receptor-3 / antagonists & inhibitors
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Glycoproteins / analysis. Humans. Lymphangiogenesis / drug effects. Mice. Mice, Inbred BALB C. Phosphorylation. Vascular Endothelial Growth Factor C / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2000 Mar;19(1):113-20 [10840945.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1530-41 [17101326.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] Clin Exp Metastasis. 2000;18(4):321-7 [11448063.001]
  • [Cites] FASEB J. 2002 Jul;16(9):922-34 [12087053.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1413-9 [12091074.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8848-52 [14695201.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):875-9 [15012985.001]
  • [Cites] Am J Surg. 2004 Sep;188(3):327-32 [15450843.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1096-103 [8855981.001]
  • [Cites] Clin Exp Metastasis. 1998 May;16(4):389-98 [9626818.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):893-900 [15546507.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1639-49 [15634658.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):314-8 [15783058.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):388-92 [15688374.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):451-5 [16053517.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8364-71 [16322297.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):228-40 [16344322.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2224-30 [16416166.001]
  • [Cites] Int J Clin Oncol. 2006 Feb;11(1):38-43 [16508727.001]
  • [Cites] J Pathol. 2001 Feb;193(2):143-6 [11180158.001]
  • (PMID = 19738610.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Ki23057; 0 / Quinolines; 0 / Vascular Endothelial Growth Factor C; 0 / Xlkd1 protein, mouse; 0 / vascular endothelial growth factor C, mouse; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  • [Other-IDs] NLM/ PMC2768106
  •  go-up   go-down


5. Trojan J, Kim SZ, Engels K, Kriener S, Mitrou PS, Chow KU: In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer. Anticancer Drugs; 2005 Jan;16(1):87-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
  • Individual response of disseminated cancer to chemotherapy is unpredictable.
  • In vitro chemotherapy-induced apoptosis can be measured and might be a method to evaluate in vivo activity of tested drugs.
  • In this report, tumor cells of a patient with signet cell carcinoma of the stomach and diffuse bone marrow infiltration were cultured and tested for in vitro chemosensitivity.
  • The drugs gemcitabine, oxaliplatin and zoledronic acid were found to induce in vitro tumor cell apoptosis synergistically, and subsequently were used as combination chemotherapy regimen.
  • An initially existing disseminated intravascular coagulopathy quickly resolved and after 6 months of treatment on ongoing complete response was induced, thus confirming the results of in vitro chemosensitivity testing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Deoxycytidine / analogs & derivatives. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Diphosphonates / administration & dosage. Drug Screening Assays, Antitumor. Humans. Imidazoles / administration & dosage. Male. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Predictive Value of Tests. Remission Induction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613910.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6XC1PAD3KF / zoledronic acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


6. Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch; 2008 May;452(5):525-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas.
  • To investigate the pathobiological behaviors of gastric mixed-type (MT) carcinomas and gastric carcinogenesis, the clinicopathological characteristics of MT carcinomas were analyzed and compared with intestinal-type (IT) and diffuse-type (DT) carcinomas.
  • The expression of Ki-67, caspase-3, p53, fragile histine triad (FHIT), maspin, extracellular matrix metalloproteinase inducer (EMMPRIN), vascular growth factor (VEGF), MUC-2, 4, 5AC and 6, CD44, E-cadherin, beta-catenin, and phosphorylated glycogen synthase kinase 3beta-ser9 (P-GSK3beta-ser9) was examined on tissue microarrays using immunohistochemistry.
  • It was found that MT carcinomas exhibited large size, deep invasion, frequent local invasion, and lymph node metastasis in comparison with IT and DT carcinomas (p < 0.05).
  • All the markers except MUC-5AC showed higher expression in IT than DT carcinomas (p < 0.05).
  • The expression of maspin, EMMPRIN, VEGF, MUC-4, and membrane E-cadherin was stronger in MT intestinal than diffuse component (p < 0.05).
  • Immunoreactivities to Ki-67, EMMPRIN, and VEGF were weaker in IT carcinoma than in the MT intestinal portion (p < 0.05), while the opposite was true for CD44, MUC-2, and MUC-6 (p < 0.05).
  • The MT diffuse component displayed a higher expression of FHIT, VEGF, and P-GSK3beta-ser9 than DT carcinoma (p < 0.05).
  • The accumulative survival rate of the IT carcinoma patients was higher than the other types (p < 0.05).
  • These findings suggested that MT carcinomas were also indicated to be more aggressive than IT and DT carcinomas.
  • Significant differences were observed in the proliferation, apoptosis, angiogenesis, mucin secretion, and cell adhesion between IT and DT carcinomas, whereas only a few of these characteristics showed differences between the MT intestinal and diffuse parts, thus suggesting that both the MT components might originate from the stem cells with similar genetic traits, but follow different histogenic pathways.
  • [MeSH-major] Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Malignant / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • [Cites] Oncology. 1995 Jul-Aug;52(4):334-9 [7539903.001]
  • [Cites] Gen Diagn Pathol. 1997 Jul;143(1):39-48 [9269907.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133 [15895459.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):363-71 [16489634.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2353-60 [16821616.001]
  • [Cites] Gastric Cancer. 2006;9(3):177-84 [16952035.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):259-65 [17352241.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] J Pathol. 2000 Mar;190(4):437-43 [10699992.001]
  • [Cites] Br J Surg. 2000 May;87(5):618-26 [10792320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):75-8 [11205493.001]
  • [Cites] Chem Rev. 2001 Aug;101(8):2527-40 [11749387.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Gastric Cancer. 2004;7(2):61-77 [15224192.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1989 Jan;11(1):37-40 [2550197.001]
  • [Cites] Cancer. 1990 May 1;65(9):2086-90 [2372774.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):103-11 [7903667.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • (PMID = 18266006.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2329735
  •  go-up   go-down


7. Fujita T, Fukuda K, Nishi H, Takao T, Ohmura Y, Mano M, Komatsubara S, Yano T: [A case of effective response to TS-1 of inoperable gastric cancer, in the course of chemotherapy for malignant lymphoma]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1977-81
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective response to TS-1 of inoperable gastric cancer, in the course of chemotherapy for malignant lymphoma].
  • We encountered a case of effective response to TS-1 of inoperable gastric cancer, in the course of chemotherapy for malignant lymphoma.
  • A 78-year-old man, in the course of chemotherapy for malignant lymphoma, complained of appetite loss.
  • A biopsy from gastric endoscopy indicated gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Humans. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650971.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


8. Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M, Shinagawa K, Tanaka S, Yasui W, Chayama K: Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci; 2010 Sep;101(9):1984-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma.
  • Thus, we investigated the relation between PDGF and PDGF receptor (PDGF-R) expression and lymphatic metastasis in human gastric carcinoma.
  • We examined PDGF-B and PDGF-Rβ expression in four human gastric carcinoma cell lines (TMK-1, MKN-1, MKN-45, and KKLS) and in 38 surgical specimens of gastric carcinoma.
  • PDGF-B and PDGF-Rβ expression was examined by immunofluorescence in surgical specimens and in human gastric carcinoma cells (TMK-1) implanted orthotopically in nude mice.
  • PDGF-B and PDGF-Rβ mRNA expression was significantly higher in patients with lymph node metastasis than in those without and was also significantly higher in diffuse-type carcinoma than in intestinal-type carcinoma.
  • Four weeks of treatment with imatinib significantly decreased the area of lymphatic vessels.
  • Our data indicate that secretion of PDGF-B by gastric carcinoma cells and expression of PDGF-Rβ by tumor-associated stromal cells are associated with lymphatic metastasis.
  • Blockade of PDGF-R signaling pathways may inhibit lymph node metastasis of gastric carcinoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins c-sis / genetics. Receptor, Platelet-Derived Growth Factor beta / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Animals. Benzamides. Blotting, Western. Cell Line, Tumor. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Lymphatic Metastasis. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Piperazines / pharmacology. Protein Kinase Inhibitors / pharmacology. Pyrimidines / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Cancer Association.
  • (PMID = 20624165.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-sis; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


9. Ochiai T, Sonoyama T, Kikuchi S, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Ueda Y, Otsuji E, Hagiwara A, Yamagishi H: [Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1815-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma].
  • We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU).
  • A 74-year-old man underwent distal gastrectomy 6 years ago for gastric cancer.
  • In April 2002, an increased serum alpha-feto-protein (AFP) level was noted and a computed tomography (CT) of the abdomen revealed a diffuse type of HCC.
  • He was treated with a combination therapy of IFN (5x10(6) units/body i.m., days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26) and 5-FU (500 mg/body/day i.a., days 1-5, 8-12 continuously).
  • The treatment was repeated every 4 weeks with a maximum of five cycles.
  • He has been well and continue to receive IFN (3x10(6) units/body i.m., two times a week) and 5-FU (500 mg/body/day i.a., once a week) at the outpatient clinic for the last 16 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Drug Administration Schedule. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Injections, Intramuscular. Interferon-alpha / administration & dosage. Male. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553725.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Nakai S, Masaki T, Shintani T, Deguchi A, Kimura Y, Himoto T, Kurokohchi K, Watanabe S, Kuriyama S: Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma. Oncol Rep; 2005 Jun;13(6):1065-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
  • Here we report a case of diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody, rituximab, alone.
  • Because the patient had a complication of severe liver dysfunction due to hepatitis C virus induced-liver cirrhosis and hepatocellular carcinoma, it was difficult to treat the primary gastric lymphoma using standard therapy such as surgical resection and cocktail chemotherapy.
  • This case indicates that monotherapy using only rituximab may be a promising option for the treatment of patients with diffuse large B-cell lymphoma accompanied by severe liver dysfunction.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Cirrhosis / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Hepacivirus / pathogenicity. Hepatitis C / drug therapy. Hepatitis C / etiology. Humans. Liver Function Tests. Liver Neoplasms / drug therapy. Liver Neoplasms / etiology. Male. Rituximab. Treatment Outcome


11. Akcali Z, Sakalli H, Ozyilkan O, Demirhan B, Haberal M: Prognostically favorable abdominal breast cancer metastases with stomach involvement. Onkologie; 2005 May;28(5):270-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostically favorable abdominal breast cancer metastases with stomach involvement.
  • BACKGROUND: Abdominal metastases with stomach involvement are rare in breast cancer.
  • The median disease free interval from the time of breast cancer diagnosis to gastric metastasis is usually very long.
  • Treatment is generally palliative, and expected survival time is less than 1 year.
  • CASE REPORT: A 59-year-old woman with breast cancer developed diffuse abdominal metastases involving stomach, abdominal lymph nodes, and omentum 9 years after she underwent mastectomy and adjuvant chemotherapy.
  • The histopathologic diagnosis found by stomach specimen examination was invasive lobular carcinoma, and the cells expressed high levels of estrogen and progesterone receptors.
  • The abdominal metastases were treated with surgery, postoperative chemotherapy, and further hormonal therapy.
  • CONCLUSION: Once the definitive diagnosis of breast cancer metastases to the abdomen including the stomach is established, treatment that targets systemic breast cancer must be initiated.
  • Our patient's extended survival time suggests that surgical treatment could be considered for selected patients.
  • [MeSH-major] Abdominal Neoplasms / secondary. Breast Neoplasms / surgery. Carcinoma, Lobular / secondary. Stomach Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Gastrectomy. Humans. Mastectomy. Middle Aged. Neoplasm Invasiveness. Reoperation. Stomach / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867484.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Wai HP, Yau TK, Sze WM, Yeung MW, Hioe F, Lee AW: Metastatic tumour of the tunica vaginalis testis from carcinoma of the stomach. Int J Clin Pract; 2000 Dec;54(10):685-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumour of the tunica vaginalis testis from carcinoma of the stomach.
  • A 50-year-old man with advanced inoperable gastric adenocarcinoma and diffuse peritoneal metastasis received six cycles of palliative chemotherapy and responded clinically with weight gain.
  • Two months after the completion of chemotherapy, however, he developed a left hydrocele.
  • A diagnosis of malignant hydrocele was made.
  • Two weeks later, he developed a painful recurrent left hydrocele with increasing pain and swelling.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms. Testicular Hydrocele / etiology. Testicular Neoplasms / secondary

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11221287.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Tsai HL, Huang YS, Hsieh JS, Huang TJ, Tsai KB: Signet-ring cell carcinoma of the rectum with diffuse and multiple skin metastases--a case report. Kaohsiung J Med Sci; 2002 Jul;18(7):359-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma of the rectum with diffuse and multiple skin metastases--a case report.
  • Metastatic skin signet-ring cell carcinoma originating from stomach or colon is rare.
  • We reported a 45-year-old male who underwent abdominoperineal resection for an advanced rectal signet-ring cell carcinoma which developed multiple skin metastases in the scalp, face, neck, back and abdomen despite adjuvant chemotherapy performed postoperatively.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Rectal Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12380327.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


14. Tagami K, Tanda S, Tokumura H, Yamaguchi M: [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2891-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report].
  • We report a rare case of a collision between a gastric cancer and a malignant lymphoma with a wide systemic metastasis, combined with esophagus cancer, stomach cancer and malignant lymphoma.
  • He was diagnosed with malignant diffuse large B cell lymphoma by immunostaining from the extirpated right testis.
  • He received six cycles of R-CHOP therapy.
  • Thereafter, we performed MTX-HOPE therapy as a salvage therapy for four cycles.
  • During this chemotherapy, he felt epigastralgia; esophagus cancer (squamous cell carcinoma) and stomach cancer (highly-differentiated adenocarcinoma) were found by upper endoscopy.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160264.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Taal BG, Peterse H, Boot H: Clinical presentation, endoscopic features, and treatment of gastric metastases from breast carcinoma. Cancer; 2000 Dec 1;89(11):2214-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, endoscopic features, and treatment of gastric metastases from breast carcinoma.
  • BACKGROUND: Breast carcinoma is the most common malignancy in women.
  • Metastatic involvement of the stomach is not well known.
  • METHODS: Endoscopic features and treatment options were evaluated retrospectively for 51 patients with gastric metastases of breast carcinoma.
  • RESULTS: The presenting sites of metastases were skeleton (43%), stomach (27%), lung (8%), and liver (4%).
  • Diagnosis of gastric involvement was histologically confirmed in 41 patients and based on endoscopic features, despite negative biopsies in 10 patients.
  • Endoscopy showed 3 patterns: 18% localized lesions, 57% diffuse infiltration, and 25% external compression at the cardia or pylorus.
  • Histology showed mainly lobular breast carcinoma (n = 36) compared with ductal carcinoma (n = 10) and other types (n = 5), contrary to the usual distribution.
  • The overall response to systemic therapy was 46% (17 of 37 treated patients).
  • Median survival from detection of gastric metastases was 10 months, with a 2-year survival rate of 23%.
  • CONCLUSIONS: Gastric metastases usually derive from lobular rather than ductal breast carcinoma.
  • Endoscopy revealed mainly a diffuse linitis plastica-like infiltration.
  • Chemotherapy or hormonal treatment may result in fair palliation in selected patients, although many patients are heavily pretreated.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Gastroscopy. Stomach Neoplasms / secondary. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Carcinoma, Lobular / therapy. Female. Humans. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11147591.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ueo T, Kashima K, Daa T, Kondo Y, Yokoyama S: Coexistence of Epstein-Barr virus-associated gastric carcinoma with malignant lymphoma: report of two cases. Virchows Arch; 2006 Aug;449(2):215-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of Epstein-Barr virus-associated gastric carcinoma with malignant lymphoma: report of two cases.
  • Epstein-Barr virus (EBV)-associated gastric carcinoma (EBV-GC) is not rare, accounting for 5 to 18% of all gastric carcinomas.
  • Recently, we encountered two cases of EBV-GC of ordinary histopathological type coexistent with malignant lymphoma.
  • One patient was a 71-year-old Japanese man who had two lesions, one in the cardia and the other in the antrum of the stomach.
  • The former was EBV-GC without lymphoma, and antral one was EBV-GC with diffuse large B-cell lymphoma (DLBCL).
  • The other patient was a 49-year-old Japanese man who had received chemotherapy for pelvic DLBCL 3 years earlier.
  • He had EBV-GC with follicular lymphoma in the fundus of the stomach.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Lymphoma / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Mar 15;79(6):1077-85 [9070483.001]
  • [Cites] J Pathol. 2003 Oct;201(2):312-8 [14517849.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):612-8 [11522745.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):396-7 [1317885.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2475-80 [2835144.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):3-11 [8988720.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):34-6 [15027715.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):360-7 [9211523.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4237-42 [6272968.001]
  • [Cites] Am J Pathol. 1991 Jan;138(1):149-63 [1846263.001]
  • [Cites] Gastric Cancer. 1998 Mar;1(2):104-114 [11957053.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • [Cites] Histopathology. 1996 Jul;29(1):51-6 [8818694.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):174-81 [8607441.001]
  • [Cites] Cancer. 1996 May 15;77(10):1998-2004 [8640662.001]
  • [Cites] Gastric Cancer. 1999 Aug;2(2):101-108 [11957081.001]
  • [Cites] Hum Pathol. 1991 Aug;22(8):811-5 [1651284.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1063-71 [8214002.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):264-8 [1646459.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] Hum Pathol. 1995 Mar;26(3):267-71 [7890276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Acta Pathol Jpn. 1993 Oct;43(10):574-81 [8291445.001]
  • (PMID = 16609909.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


17. Jones-Bolin S, Ruggeri B: Orthotopic models of human gastric carcinoma in nude mice: applications for study of tumor growth and progression. Curr Protoc Pharmacol; 2007 Jun;Chapter 14:Unit 14.4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthotopic models of human gastric carcinoma in nude mice: applications for study of tumor growth and progression.
  • Gastric carcinoma (GC) remains a leading cause of cancer related deaths worldwide with the 5-year survival rate in the U.S. at -5% to 15% with existing therapies.
  • This tumor is aggressive and has often metastasized to distant sites (liver, lung, and adjacent intestine) by the time of diagnosis.
  • Treatment options (surgery, radiation, and chemotherapy) are limited and the disease carries a grave prognosis for most patients (50% 5-year survival for distal GC; 10% 5-year survival for proximal GC).
  • An orthotopic model of human GC in nude mice provides an excellent way to evaluate the pathogenesis of tumor growth and metastasis in order to develop effective therapies, as well as to better understand the underlying biology of gastric tumor growth and metastasis.
  • The protocol described in this unit details the development and characterization of an orthotopic model of human GC in athymic nude mice with diffuse lymphatic and hepatic metastatic spread.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21948163.001).
  • [ISSN] 1934-8290
  • [Journal-full-title] Current protocols in pharmacology
  • [ISO-abbreviation] Curr Protoc Pharmacol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ramesh S, Shanthi P, Krishnan KB, Shanthi AV, Taralakshmi VV, Subulakshmi S: Multidrug resistance 1 gene expression in Indian patients with gastric carcinoma. Indian J Gastroenterol; 2003 Jan-Feb;22(1):19-21
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance 1 gene expression in Indian patients with gastric carcinoma.
  • BACKGROUND: Gastric carcinoma is frequently refractory to chemotherapy.
  • The multidrug resistance 1 gene (MDR1) encodes for a protein (p-glycoprotein) that functions as a drug efflux pump and thus contributes to resistance to chemotherapeutic agents.
  • METHODS: We studied gastric tissues from 28 patients with gastric cancer for MDR1 expression, using immunohistochemistry.
  • Sections of normal mucosa away from the tumor showed perinuclear staining for MDR1 in surface epithelial cells, whereas tumor cells showed diffuse cytoplasmic positivity.
  • CONCLUSIONS: Over one half of gastric carcinoma specimens at our center show MDR1 gene expression.
  • [MeSH-major] Genes, MDR / physiology. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12617447.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


19. Funk L, Hartmann D, Apel D, Spiethoff A, Schiele R, Schilling D, Adamek HE, Riemann JF: [Symptomatic pericardial effusion as initial manifestation of gastric signet ring cell carcinoma]. Dtsch Med Wochenschr; 2003 Apr 17;128(16):870-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Symptomatic pericardial effusion as initial manifestation of gastric signet ring cell carcinoma].
  • The health history included the diagnosis of diabetes mellitus and chronic obstructive pulmonary disease.
  • The cytology showed signet ring cells from the stomach.
  • The histopathological examination diagnosed cancer of diffuse type according to Lauren, with signet-ring cells.
  • TREATMENT AND CLINICAL COURSE: After treating the atrial fibrillation a pericardial drainage was performed.
  • During the clinical course the patient suffered a stroke and the chemotherapy could not be initiated.
  • The patient died 2 months after diagnosis.
  • Echocardiography and pericardiocentesis are helpful for the diagnosis of cardiac metastases.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Pericardial Effusion / etiology. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Atrial Fibrillation / diagnosis. Atrial Fibrillation / etiology. Atrial Fibrillation / therapy. Drainage. Dyspnea. Fatal Outcome. Female. Gastroscopy. Humans. Pericardiocentesis. Tachycardia

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701032.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M: Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer; 2004;7(4):240-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although some clinical trials have indicated that chemotherapy and immunochemotherapy may be effective modalities, more recent studies have not been able to define the standard treatment for advanced gastric cancer.
  • The present study evaluated the effect of adjuvant immunochemotherapy with the use of BCG (bacille Calmette-Guerin) and FAM (5-fluorouracil, adriamycin, mitomycin C) chemotherapy on the survival of patients with locally advanced resectable gastric cancer.
  • METHODS: A total of 156 patients with stage III or IV gastric cancer who had undergone curative resection were randomly assigned to three treatment groups: BCG + FAM (immunochemotherapy), FAM (chemotherapy), and control (surgery only).
  • Treatment was continued for 2 years or until death.
  • RESULTS: Overall 10-year survival was 47.1% for the immunochemotherapy group (P < 0.037 vs FAM and P < 0.0006 vs control), 30% for the chemotherapy group (vs control, NS), and 15.2% for the control group.
  • BCG + FAM significantly improved the survival of patients with intestinal-type but not diffuse-type cancer.
  • CONCLUSION: This study, based on a limited number of patients, indicates that adjuvant immunochemotherapy (BCG + FAM) may prolong the survival of gastric cancer patients after curative gastrectomy; in particular, in patients with pT2/T3 tumors and intestinal-type primary tumors.
  • There was no survival benefit from FAM adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Immunotherapy. Male. Middle Aged. Mitomycin / administration & dosage. Mycobacterium bovis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15616772.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


21. Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K: Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep; 2000 Jul-Aug;7(4):841-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combination of 5-fluorouracil (5-FU) and cisplatin is used most commonly for gastric carcinoma.
  • Recent studies have indicated that vascular endothelial growth factor (VEGF) is related to drug delivery through angiogenesis and vascular permeability.
  • In this study, we evaluated the efficacy and toxicity of continuous infusion of 5-FU and low dose cisplatin infusion as first-line treatment in patients with unresectable gastric adenocarcinoma.
  • We also examined the relationship between chemotherapy response and immunohistochemical expression of VEGF in the biopsy samples of gastric primary.
  • This treatment was repeated weekly for 3 consecutive weeks.
  • Patients with intestinal histologic type (10/12) and good performance status ([PS], 13/18) showed good response rate (83.3%, and 72.2%, respectively) compared to patients with diffuse histologic type (4/18) and poor PS [(1/12) 22.2%, and 8.
  • Multivarite analysis revealed that VEGF-positive and good PS had a significant impact on chemotherapy response in this treatment.
  • Continuous infusion of 5-FU and low dose cisplatin infusion is an effective treatment for patients with unresectable gastric carcinoma, and VEGF expression may be a useful predictor of chemotherapy response in this regimen.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endothelial Growth Factors / analysis. Lymphokines / analysis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biopsy. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Infusions, Intravenous. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Survival Rate. Time Factors. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10854555.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Tokar M, Bobilev D, Ariad S, Geffen DB: Disseminated intravascular coagulation at presentation of advanced gastric cancer. Isr Med Assoc J; 2006 Dec;8(12):853-5
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Disseminated intravascular coagulation associated with malignant bone marrow involvement has been described as a rare complication of gastric carcinoma and most patients die within 1-4 weeks.
  • Effective chemotherapy of the underlying malignancy may be the only way to control acute DIC.
  • OBJECTIVES: To assess the benefit of infusional 5-fluorouracil as the primary treatment of metastatic gastric carcinoma and DIC at diagnosis.
  • METHODS: From February 2001 to January 2005, six women (median age 48 years) with gastric carcinoma who presented with diffuse bone metastases and acute DIC were treated in our department.
  • Diagnosis was based on primary gastric and bone marrow biopsies.
  • Initial treatment consisted of infusional 5FU 200 mg/m2/day.
  • RESULTS: Within one week of starting the treatment, the clinical and laboratory signs of acute DIC were resolved in five of six patients.
  • CONCLUSIONS: Based on our experience, infusional 5FU is an effective regimen with negligible myelosuppression; thus, it may be a good choice as initial therapy for this group of patients.
  • Therefore, once DIC symptoms are controlled, the addition of newer cytotoxic drugs may be necessary to consolidate the remission.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Disseminated Intravascular Coagulation / etiology. Fluorouracil / therapeutic use. Stomach Neoplasms / drug therapy. Treatment Outcome
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow Neoplasms / secondary. Cisplatin / therapeutic use. Disease Progression. Epirubicin / therapeutic use. Female. Humans. Infusions, Intravenous. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214103.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Nathan JD, Gingalewski C, Salem RR: Intra-abdominal desmoplastic small round cell tumor. Yale J Biol Med; 2001 Jan-Feb;74(1):13-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aggressive nature of tumor spread, relative insensitivity to chemotherapy, and generally incomplete resectability result in a very poor prognosis.
  • The authors report a case of a 39-year-old man with diffuse abdominal and pelvic involvement of intra-abdominal desmoplastic small round cell tumor treated with aggressive chemotherapy and surgery.
  • METHODS: Computed tomography (CT)-guided biopsy of an omental mass was performed.
  • On the basis of these unique histological and immunohistochemical characteristics, the diagnosis of desmoplastic small round cell tumor was made.
  • The patient was treated with aggressive neoadjuvant chemotherapy consisting of a high-dose alkylator -based combination regimen, followed by surgery.
  • RESULTS: The patient had a 10 to 15 percent regression in tumor mass in response to chemotherapy.
  • Although some response to chemotherapy may be possible, complete resection is rare, and surgical efforts are generally palliative.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1314-27 [9808124.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):416-22 [9718171.001]
  • [Cites] Tumori. 1998 May-Jun;84(3):412-6 [9678628.001]
  • [Cites] Semin Diagn Pathol. 1996 Aug;13(3):204-12 [8875710.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] Am J Surg Pathol. 1990 Jul;14(7):633-42 [2356923.001]
  • [Cites] Histopathology. 1991 Jan;18(1):45-51 [1707394.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] Histopathology. 1991 Dec;19(6):560-2 [1786939.001]
  • [Cites] Am J Surg Pathol. 1992 Apr;16(4):411-6 [1314522.001]
  • [Cites] Acta Cytol. 1992 May-Jun;36(3):373-6 [1580121.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Dec;64(2):189-91 [1486572.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Nov;5(4):271-7 [1283315.001]
  • [Cites] Pathol Res Pract. 1992 Dec;188(8):981-8 [1300610.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Jun;7(2):119-21 [7687454.001]
  • [Cites] Zentralbl Pathol. 1993 Jun;139(2):141-51 [8396418.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Aug;69(1):17-21 [8374894.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):850-65 [8375856.001]
  • [Cites] Med Pediatr Oncol. 1994;22(2):97-102 [7505050.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1753-6 [7512439.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):659-65 [7755152.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1363-6 [8608516.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1526-31 [8622067.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Aug;18(3):293-8 [8689345.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):845-51 [8756380.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 1;108(1):19-25 [9973919.001]
  • [Cites] Pathol Res Pract. 1998;194(10):693-700 [9820865.001]
  • (PMID = 11249235.001).
  • [ISSN] 0044-0086
  • [Journal-full-title] The Yale journal of biology and medicine
  • [ISO-abbreviation] Yale J Biol Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2588677
  •  go-up   go-down


26. Park SY, Kook MC, Kim YW, Cho NY, Kim TY, Kang GH: Mixed-type gastric cancer and its association with high-frequency CpG island hypermethylation. Virchows Arch; 2010 Jun;456(6):625-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type gastric cancer and its association with high-frequency CpG island hypermethylation.
  • Gastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found.
  • A significant difference was observed between the number of methylated genes in Epstein-Barr virus (EBV)-negative and microsatellite instability (MSI)-negative GCs of different histological types (Lauren classification; P < 0.01).
  • We found that mixed-type (MT) carcinomas, which have both diffuse-type (DT) and intestinal-type (IT) components, had more methylated genes (10.6) than either DT carcinomas (7.6 methylated genes) or IT carcinomas (6.7 methylated genes) (P < 0.001).
  • When the IT and DT components were dissected from MT carcinomas and the methylation of these 16 genes was evaluated, both components had a number of methylated genes similar to MT carcinomas, (10.2 and 9.7, respectively), which was significantly higher than was found in IT and DT carcinomas (P < 0.05).
  • These findings indicate that MT carcinoma is distinct from IT and DT carcinomas in its enhanced CpG island hypermethylation status and implicate the enhanced promoter CpG island hypermethylation in the histogenesis of MT carcinoma.
  • [MeSH-major] CpG Islands. DNA Methylation. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2008 May;452(5):525-34 [18266006.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):307-15 [8658214.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):209-17 [16645207.001]
  • [Cites] Lab Invest. 2008 Feb;88(2):161-70 [18158559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] J Biochem Mol Biol. 2007 Mar 31;40(2):142-50 [17394762.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):238-46 [15609344.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1175-83 [16931963.001]
  • [Cites] J Pathol. 2009 Dec;219(4):410-6 [19639607.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2995-3002 [16707594.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Carcinogenesis. 1999 Dec;20(12):2195-208 [10590210.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1412-7 [16432200.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Dec;14(12):1150-60 [10634150.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Sci. 2007 Dec;98(12):1853-61 [17900260.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1250-9 [16475210.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):787-94 [11891177.001]
  • [Cites] Bull Am Coll Surg. 2002 Jul;87(7):13-5 [17387902.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):279-87 [18308253.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):13-27 [18165277.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):656-63 [15701853.001]
  • [Cites] Virchows Arch. 2008 May;452(5):515-24 [18335237.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1467-79 [16518809.001]
  • (PMID = 20422213.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins
  •  go-up   go-down


27. Ajani J, D'Amico TA, Hayman JA, Meropol NJ, Minsky B, National Comprehensive Cancer Network: Gastric cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw; 2003 Jan;1(1):28-39
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse histology is also more common now than intestinal type of histology.
  • Patients with locoregional gastric carcinoma should also be referred to high-volume treatment centers.
  • Combination chemotherapy and radiotherapy in the adjuvant setting for select group of patients is considered the new standard in the United States.
  • We look forward to the results of investigations of a number of new chemotherapeutic agents, including antireceptor agents, vaccines, gene therapy, and antiangiogenic agents.
  • The panel anticipates many advances in the treatment of esophageal carcinoma in the future.
  • [MeSH-major] Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764148.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


28. Mader AM, Patrício FR, Rigueiro MP, Lourenço LG: [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia]. Arq Gastroenterol; 2006 Jul-Sep;43(3):184-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: In view of the increased incidence of carcinoma of the cardia over recent years, this work had the aim of studying the clinicopathological aspects, cell proliferative and tumor apoptotic indices of this neoplasm, their interrelations and possible influences on the prognosis.
  • Patients were excluded if they had previous chemotherapy or radiotherapy treatment, presented early neoplasia, or died during the operations or for other reasons unrelated to cancer.
  • Gender; age, Laurén and Ming histological type, staging, and the presence or absence of intestinal metaplasia, epithelial dysplasia and Helicobacter pylori in the adjacent mucosa were analyzed.
  • For the survival analysis, cases with distant metastasis upon diagnosis were excluded.
  • There was predominance of the male gender (72.5%), diffuse histological type (55%) and infiltrative histological type (72.5%), and the more advanced stages (III and IV: 67.5%).
  • There was a positive correlation for intestinal histological type with PCNA and apoptotic indices, in 10 high power fields.
  • CONCLUSIONS: Adenocarcinoma of the cardia predominated in male adults of mean age 61 years, and the predominant type was diffuse in more advanced stages.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cardia / pathology. Cell Proliferation. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160232.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


29. Popiela T, Kulig J, Kołodziejczyk P, Polish Gastric Cancer Study Group: The relationship between improved prognosis in gastric cancer patients in the last 25 years and changing methods of surgical and combined treatment. Przegl Lek; 2000;57 Suppl 5:9-13
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between improved prognosis in gastric cancer patients in the last 25 years and changing methods of surgical and combined treatment.
  • BACKGROUND: Poland is among the countries with the high morbidity and mortality rates for gastric carcinoma (GC).
  • METHODS: Based on the prospectively collected data of 3696 GC patient treated surgically between 1977-1999, potentially significant prognostic factors were analyzed to assess their prognostic value, and their time related distribution during the over 20-year period of the study.
  • In the over 20-year period of study the rate of diffuse type carcinoma acc. to Lauren increased but the tumor locations did not changed significantly.
  • Chemo- and chemotherapy improved outcomes in some groups of patients.
  • According to the obtained results the prognosis of GC depends clearly upon the stage of the disease at the time of surgery.
  • The improvement of outcomes during over 20 years of GC study in Poland was due to introducing better diagnosis and routine multimodal treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Gastrectomy / methods. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. BCG Vaccine / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Pilot Projects. Prognosis. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11202309.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / BCG Vaccine; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; EAP protocol; FAM protocol
  •  go-up   go-down


30. Lazăr D, Tăban S, Sporea I, Dema A, Cornianu M, Lazăr E, Goldiş A, Vernic C: Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol; 2010;51(4):655-61
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor cells were considered Ki-67 positive in the presence of brown nuclear staining of granular or diffuse type.
  • We noticed an increased frequency of high MI Ki-67 carcinomas in elderly patients (p=0.03) and also in the tumors developed at cardia level and those extended in the entire stomach in the moment of diagnosis (p<0.001).
  • The histological forms associated to high Ki-67 values are represented by the anaplastic carcinoma (100% of cases) and papillary adenocarcinoma (60% of cases).We observed a close correlation between the degree of tumor differentiation and the Ki-67 score (p<0.001).
  • CONCLUSIONS: In our study, immunohistochemical assessment of the tumor proliferation does not represent a prognostic factor, but seems to be useful in identifying of a group of patients with aggressive tumors, needing adjuvant postoperatory chemotherapy.
  • [MeSH-major] Ki-67 Antigen / metabolism. Stomach Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103622.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


31. Waguri N, Furukawa K, Shobugawa K, Takizawa K, Ikeda H, Iwamoto Y, Aiba T, Yoneyama O, Igarashi K, Tsukioka S, Yabe M, Kuwabara S, Shibuya H: [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1151-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy].
  • Here we report a case of gastric cancer with diffuse abdominal wall invasion treated with weekly low-dose paclitaxel therapy.
  • Computed tomography revealed diffuse swelling of the abdominal wall and hydronephrosis of the right kidney.
  • Upper gastrointestinal endoscopy demonstrated type 3' advanced gastric cancer.
  • Pathological diagnosis of both gastric tumor and abdominal wall biopsy specimens was poorly-differentiated adenocarcinoma containing signet ring cell carcinoma.
  • Abdominal wall swelling like cuirass disappeared after 2 courses of low-dose paclitaxel therapy.
  • Diffuse abdominal wall invasion of gastric cancer like cuirass without ascites is a rare condition, and low-dose paclitaxel was very effective for this condition.
  • [MeSH-major] Abdominal Wall / pathology. Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Signet Ring Cell / pathology. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Invasiveness. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912538.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


32. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci; 2006 Aug;51(8):1371-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HER-2/neu protein is intimately involved with normal cell proliferation and tissue growth and is extensively homologous and related to the epidermal growth factor receptor.
  • HER-2/neu protein expression has been most intensively studied in the context of breast carcinoma, in which its amplification and overexpression correlate with the overall course of disease, and with a poor prognosis, and constitute a predictive factor of poor response to chemotherapy and endocrine therapy.
  • This study was performed with a view toward the future introduction of Herceptin therapy for gastric cancer patients.
  • Intestinal-type cancers exhibited higher rates of HER-2/neu amplification than did diffuse-type cancers (P < 0.05).
  • HER-2/neu amplification may constitute an independent prognostic factor in gastric cancer patients, and patients exhibiting HER-2/neu amplification might constitute potential candidates for new adjuvant therapies which involve the use of humanized monoclonal antibodies.
  • [MeSH-major] Carcinoma / metabolism. DNA, Neoplasm / genetics. Gene Amplification. Receptor, ErbB-2 / genetics. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Dec 1;72(11):3179-84 [7902202.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Eur J Cancer. 1996 Jan;32A(1):63-8 [8695243.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Pathol Int. 1997 Feb-Mar;47(2-3):179-82 [9088037.001]
  • [Cites] J Pathol. 1989 Oct;159(2):107-11 [2572685.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):668-71 [1676988.001]
  • [Cites] EMBO J. 1987 Mar;6(3):605-10 [3034598.001]
  • [Cites] J Surg Oncol. 1992 Apr;49(4):209-12 [1348293.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1034-8 [1670998.001]
  • [Cites] Int J Cancer. 1993 Jan 2;53(1):75-9 [8093216.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1204-7 [11688582.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):8002-9 [1979253.001]
  • [Cites] Oncogene. 1996 Jul 4;13(1):63-72 [8700555.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):454-6 [1350789.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):584-9 [8099338.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1418-25 [7889468.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2914-8 [1673870.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):2896-907 [7954254.001]
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):294-8 [9058162.001]
  • [Cites] Diagn Mol Pathol. 2001 Sep;10(3):139-52 [11552716.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):556-62 [11406656.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Br J Cancer. 1991 Jul;64(1):79-83 [1677259.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):761-8 [9284825.001]
  • [Cites] Tumour Biol. 1994;15(5):294-303 [7991990.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3942-6 [8099528.001]
  • [Cites] Oncogene. 1989 Jan;4(1):81-8 [2563577.001]
  • [Cites] EMBO J. 1993 Jun;12(6):2369-75 [8099545.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2083-8 [8397058.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] Jpn J Cancer Res. 1988 Apr;79(4):439-44 [3133334.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):213-8 [11266529.001]
  • (PMID = 16868827.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


33. Ohno T, Yokoyama Y, Aihara R, Mochiki E, Asao T, Kuwano H: Sudden bilateral sensorineural hearing loss as the presenting symptom of meningeal carcinomatosis of gastric cancer: report of a case. Surg Today; 2010 Jun;40(6):561-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal carcinomatosis is the diffuse infiltration of the meninges by metastatic carcinoma.
  • Upper gastrointestinal endoscopy revealed a large type 3 gastric cancer, and the pathological diagnosis was poorly differentiated adenocarcinoma.
  • Although combination chemotherapy with oral S-1 and weekly paclitaxel and radiation therapy were performed, the patient's condition gradually worsened, and he eventually died 12 weeks after the onset of deafness.
  • [MeSH-major] Adenocarcinoma / secondary. Hearing Loss, Bilateral / etiology. Hearing Loss, Sensorineural / etiology. Hearing Loss, Sudden / etiology. Meningeal Carcinomatosis / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Sensorineural hearing loss.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otol. 1992 Jul;13(4):369-71 [1415503.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1642-7 [17133268.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1655-62 [3309199.001]
  • [Cites] J Clin Neurosci. 2005 Apr;12(3):315-8 [15851093.001]
  • [Cites] Brain Nerve. 2007 Dec;59(12):1385-9 [18095490.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):517-27 [12057097.001]
  • [Cites] N Engl J Med. 1973 Oct 11;289(15):770-3 [4517004.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Jan;106(1):92-7 [1734379.001]
  • [Cites] J R Coll Surg Edinb. 1998 Apr;43(2):119-21 [9621540.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):68-73 [3079822.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Arch Neurol. 1996 Jul;53(7):626-32 [8929170.001]
  • [Cites] Arch Neurol. 1974 Feb;30(2):122-37 [4405841.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 May;124(5):592-4 [11337674.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Surg Today. 2008;38(12):1102-7 [19039635.001]
  • [Cites] Neurol Sci. 2005 Feb;25(6):345-7 [15729499.001]
  • [Cites] Surg Today. 2008;38(5):445-8 [18560969.001]
  • (PMID = 20496139.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Kath R, Fiehler J, Schneider CP, Höffken K: Gastric cancer in very young adults: apropos four patients and a review of the literature. J Cancer Res Clin Oncol; 2000 Apr;126(4):233-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prior to diagnosis, all three women had recently been pregnant (1-22 months).
  • Diagnosis was endoscopically biopsy-proven and staging work-up was performed by primary explorative surgery (n = 1), laparoscopy and explorative surgery (n = 1) or CAT scan and ultrasound (n = 2).
  • The delay between initial symptoms and diagnosis was 8-22 weeks (median, 10 weeks).
  • All patients had the diffuse type of gastric cancer according to Lauren.
  • The best response after chemotherapy was partial in two patients.
  • Three patients died 6, 4 and 8 months after diagnosis.
  • Though the delay between the first symptoms and diagnosis in our patients was no different from that reported for older patients, special emphasis should be given to prompt referral and diagnostic investigations, ensuring the diagnosis of gastric cancer early in the course of disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Age Factors. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Female. Floxuridine / therapeutic use. Helicobacter pylori / isolation & purification. Humans. Leucovorin / therapeutic use. Male. Pregnancy. Pregnancy Complications, Neoplastic. Preoperative Care. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782897.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; FLAP protocol
  • [Number-of-references] 28
  •  go-up   go-down


35. Adán-Merino L, Gómez-Senent S, Froilán-Torres C, Suárez J, Martín- Arranz E, Larrauri J, Mora-Sanz P, Segura-Cabral JM, Aldeguer-Martinez M: [Gastric adenocarcinoma in young adults; comparative study with older patients]. Rev Gastroenterol Mex; 2010;75(3):253-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lauren diffuse type carcinoma was more frequent in people younger than 35 years (70%) than in older patients (17.4%).
  • Surgical resection was performed in 68% of cases and the rest received only systemic chemotherapy.
  • For this reason is important to be aware of alarm symptoms and risk factors in order to perform an early endoscopic diagnosis and a treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Databases, Factual. Female. Humans. Male. Mexico / epidemiology. Middle Aged. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959173.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


36. Cserni G, Vágó T, Török N, Gaál Z, Velkei T, Serényi P, Göczo K, Tusa M, Kovács K, Szucs M: [Carcinomatous meningitis]. Lege Artis Med; 2007 Oct;17(10):688-93
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORTS: A 53-year-old woman with a recent history of breast cancer (pT2pN2M0) had been treated by mastectomy and adjuvant chemotherapy and radiotherapy.
  • The rapidly progressive neurological symptoms and the history of breast cancer and findings suggesting pancreatic head tumour, respectively, led to the clinical diagnosis of carcinomatous meningitis in both cases, despite any evidence on CT scans or a negative MR scan, though of limited value, in the first case.
  • This diagnosis was confirmed by the laboratory and cytological findings of the cerebrospinal fluid, and also by the post mortem examination, since both patients died within a month after the onset of the symptoms.
  • The primary tumour in the second patient proved to be a widely metastasizing diffuse type gastric cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / complications. Meningeal Carcinomatosis / etiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Ductal, Breast / complications. Diagnosis. Diplopia / etiology. Fatal Outcome. Female. Headache / etiology. Humans. Hypertension / complications. Lymphatic Metastasis. Male. Middle Aged. Muscle Weakness / etiology. Vertigo / etiology. Vomiting / etiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227599.001).
  • [ISSN] 0866-4811
  • [Journal-full-title] Lege artis medicinae : új magyar orvosi hírmondó
  • [ISO-abbreviation] Lege Artis Med
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


37. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the tumor is characterized by neoplastic proliferation with diffuse or focal areas of a vasoformative component with cavernous and arborizing channels.
  • The differential diagnosis includes a variety of benign and malignant vascular proliferations (littoral cell angioma and Kaposi's sarcoma) as well as metastatic tumors.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


38. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K, Tsutsumi Y: Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep; 2005 Nov;14(5):1223-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
  • Fluoropyrimidines [5-Fluorouracil (5-FU) and its prodrugs] have been widely used in the treatment of solid cancers.
  • The anticancer effects primarily depend on intratumoral levels of enzymes metabolizing the drugs, such as dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP), and thymidylate synthase (TS).
  • In order to know the tumor types susceptible to respective fluoropyrimidines, we investigated the expression of DPD, OPRT, TP and TS in various types of cancer with the immunoperoxidase method.
  • These four enzymes existed in all of the cancer types studied, such as pulmonary, gastric, colorectal, hepatic, cholecystic, pancreatic, renal, urocystic, and mammary cancers.
  • Respective types of cancers presented characteristic immunohistochemical features as follows: pulmonary adenocarcinoma, DPD- and TP-high; pulmonary squamous cell carcinoma, TS- and TP-high; intestinal-type gastric adenocarcinoma, TP-high; diffuse-type gastric adenocarcinoma, DPD-low and TS-high; colorectal adenocarcinoma, DPD- and TP-low, hepatocellular carcinoma, DPD-high, and TS- and OPRT-low; cholecystic adenocarcinoma, DPD- and TS-high; renal cell carcinoma, DPD-low, and OPRT- and TP-high; urocystic transitional cell carcinoma, DPD-high and OPRT-low; and mammary ductal carcinoma, OPRT-low, and TS- and TP-high.
  • The enzyme expression pattern in cancer tissue was generally similar to that of their normal counterparts.
  • However, TP immunoreactivity in adenocarcinomas of the lung, stomach and gallbladder, and urothelial carcinoma of the urinary bladder was stronger, and DPD immunoreactivity in adenocarcinoma of the breast was weaker, when compared with normal epithelial cells.
  • Fluoropyrimidine treatment may be selected, based on the simultaneous immunohistochemical evaluation of the fluoropyrimidine metabolic enzymes.
  • [MeSH-major] Antimetabolites, Antineoplastic / metabolism. Antimetabolites, Antineoplastic / pharmacology. Fluorouracil / metabolism. Fluorouracil / pharmacology. Neoplasms / drug therapy. Neoplasms / enzymology
  • [MeSH-minor] Dihydrouracil Dehydrogenase (NADP) / metabolism. Drug Resistance. Humans. Immunohistochemistry. Orotate Phosphoribosyltransferase / metabolism. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211289.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Balducci L: Cancer in the elderly: tailoring treatment. Hosp Pract (1995); 2000 Mar 15;35(3):73-9; discussion 79-80; quiz 135
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer in the elderly: tailoring treatment.
  • The body's ability to meet the stresses of cancer therapy declines in later life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Health Services for the Aged. Neoplasms / drug therapy. Patient Care Management
  • [MeSH-minor] Activities of Daily Living. Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. Carcinoma, Small Cell / drug therapy. Drug Administration Schedule. Female. Frail Elderly. Humans. Lung Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10737241.001).
  • [ISSN] 2154-8331
  • [Journal-full-title] Hospital practice (1995)
  • [ISO-abbreviation] Hosp Pract (1995)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


40. Goto E, Okamoto E, Adachi H, Fukuda Y, Ito H: Paradoxical effects by preoperative oral low-dose tegafur administration in human gastric carcinomas: enhanced apoptosis and increased intratumoral microvessel density. Oncol Rep; 2002 Sep-Oct;9(5):1021-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study examined the effect of preoperative low-dose tegafur treatment in human gastric carcinomas.
  • Among 55 patients with gastric carcinoma, 33 received an oral administration of tegafur 600 mg/body/day for 7 days before.
  • Formalin-fixed, paraffin-embedded specimens were immunostained for Ki-67, P53, P21, CD34, Bax, VEGF, and dThdPase and also examined by the terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling procedure.
  • The treatment resulted in a significant increase of mean AI in the intestinal type, in the early, and in the P53-positive carcinomas (P<0.05), while the treatment brought a significant increase of IMVD in the diffuse type, in the early and in the P53-negative carcinomas (P<0.05, respectively).
  • Preoperative low-dose tegafur treatment resulted in a paradoxical effect; enhanced apoptosis and increased IMVD in human gastric carcinomas.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Apoptosis. Carcinoma / drug therapy. Carcinoma / pathology. Neovascularization, Pathologic. Proto-Oncogene Proteins c-bcl-2. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12168067.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / BAX protein, human; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 1548R74NSZ / Tegafur; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


41. Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M, Onishi H, Katano M: Oestrogen receptor-alpha contributes to the regulation of the hedgehog signalling pathway in ERalpha-positive gastric cancer. Br J Cancer; 2010 Feb 16;102(4):738-47
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Oestrogen receptor-alpha (ERalpha) is highly expressed in diffuse-type gastric cancer and oestrogen increases the proliferation of ERalpha-positive gastric cancer.
  • Pure anti-oestrogen drug ICI 182 780 (ICI) and small interfering RNA against ERalpha (ERalpha siRNA) were used as inhibitors.
  • [MeSH-major] Carcinoma / genetics. Estrogen Receptor alpha / physiology. Hedgehog Proteins / physiology. Stomach Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Estradiol / analogs & derivatives. Estradiol / pharmacology. Estrogen Antagonists / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Humans. Signal Transduction / drug effects. Signal Transduction / genetics. Teratogens / pharmacology. Up-Regulation / drug effects. Veratrum Alkaloids / pharmacology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):3965-9 [16810741.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1050-4 [16258256.001]
  • [Cites] Int J Mol Med. 2006 Dec;18(6):1019-23 [17089004.001]
  • [Cites] J Surg Oncol. 2007 Jan 1;95(1):55-62 [17192867.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):131-44 [18166351.001]
  • [Cites] Cancer Lett. 2008 May 8;263(1):145-56 [18243529.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):731-40 [18507014.001]
  • [Cites] Gastric Cancer. 2008;11(3):168-74 [18825311.001]
  • [Cites] Development. 2000 Jun;127(12):2763-72 [10821773.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):317-28 [11487541.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):129-35 [11804739.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11217-24 [11781307.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3162-70 [12130582.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):101-12 [12635173.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):665-9 [12679906.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1575-80 [12820425.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):592-600 [12894247.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2148-51 [2720565.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1007-10 [2667745.001]
  • [Cites] Surg Today. 1992;22(5):421-5 [1421863.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):549-55 [8476768.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1318-21 [7910323.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1829-37 [14691301.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Mol Interv. 2003 Aug;3(5):281-92 [14993442.001]
  • [Cites] Science. 2004 Jun 18;304(5678):1755-9 [15205520.001]
  • [Cites] Cancer Biol Ther. 2004 Feb;3(2):165-6 [14764995.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] J Biol Chem. 1981 May 10;256(9):4341-4 [7217085.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Aug;53(2):412-7 [7251819.001]
  • [Cites] Gan To Kagaku Ryoho. 1983 Dec;10(12):2453-60 [6418074.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1376-9 [3948119.001]
  • [Cites] Nucleic Acids Res. 1988 Jan 11;16(1):369 [3340539.001]
  • [Cites] Dig Dis Sci. 1994 Dec;39(12):2689-94 [7995197.001]
  • [Cites] Brain Res Brain Res Rev. 1996 Jun;22(1):1-26 [8871783.001]
  • [Cites] Gut. 1997 Apr;40(4):516-20 [9176081.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Nov 17;240(2):478-83 [9388504.001]
  • [Cites] Br J Cancer. 1999 Jun;80(8):1271-4 [10376983.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):143-51 [15736317.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7041-9 [16849549.001]
  • (PMID = 20087349.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Estrogen Receptor alpha; 0 / Hedgehog Proteins; 0 / SHH protein, human; 0 / Teratogens; 0 / Veratrum Alkaloids; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC2837575
  •  go-up   go-down






Advertisement